The research team, led by Olivia K. A. Paulin and Jonathan P. Richardson, constructed an entire panel of mutant C. albicans strains in a single genetic background, using a recyclable CRISPR-Cas9 genome editing system. Rather than comparing knockout strains generated in different laboratories with different histories—a practice that has historically made cross-study comparisons unreliable—the researchers built homozygous single, double, triple and quadruple gene deletions additively, recycling the CRISPR cassette after each round of mutagenesis. The four genes targeted were ALS3, which encodes the hypha-associated adhesin Als3p that binds host receptors such as E-cadherin; ECE1, which encodes candidalysin, the cytolytic peptide toxin critical for host cell damage; HGC1, which encodes a G1-cyclin protein essential for maintaining hyphal morphogenesis; and SAP2, which encodes a secreted aspartyl proteinase that degrades host proteins for nutrient acquisition and immune evasion. This architecture allowed the team to evaluate each factor individually and in every meaningful combination during systemic infection in mice.

The experimental design was straightforward but powerful. Immunocompetent female C57BL/6 mice, six to seven weeks old, were injected intravenously via the tail vein with five hundred thousand C. albicans cells of either the wild-type parental strain or one of the mutant derivatives. One cohort was sacrificed three days later for quantitative organ fungal burden analysis—kidneys and brains were harvested, homogenised, serially diluted and plated onto agar in triplicate to count colony forming units. A parallel cohort was monitored daily for three weeks to measure survival, with animals humanely euthanised upon becoming moribund or losing more than twenty percent of their initial body weight. The results from these two readouts, collected across biological replicates, told strikingly different stories about the same set of fungal mutants.

The kidney findings were, at first glance, underwhelming. On day three, no mutant strain showed a significant difference in kidney fungal burden compared with wild-type, regardless of which combination of virulence genes had been deleted. The kidney is generally regarded as the principal target organ in murine systemic candidiasis, so this result suggested that Als3p, candidalysin, Hgc1p and Sap2p are collectively dispensable for controlling fungal growth in that organ. But the brain told an entirely different story. Wild-type-infected mice carried a median of approximately 5,620 colony forming units per gram of brain tissue. Deletion of ECE1 alone drove the burden up to 55,900 CFU/g, and deletion of HGC1 alone to 42,950 CFU/g. When the two deletions were combined, fungal burdens exploded to 802,000 CFU/g—a more than hundredfold increase over wild-type. Adding further deletions pushed the numbers higher still: the triple mutant lacking ALS3, ECE1 and HGC1 reached 1,230,000 CFU/g, the SAP2/ECE1/HGC1 triple mutant 1,058,000 CFU/g, and the quadruple mutant 1,375,000 CFU/g. Meanwhile, mutants retaining either ECE1 or HGC1 showed brain burdens indistinguishable from wild-type.

This pattern revealed something biologically important: hyphal formation and maintenance, governed by Hgc1p, and candidalysin production, governed by Ece1p, act in concert to restrict fungal growth in the brain—apparently by provoking protective innate immune responses. The authors connect this to established mechanisms of cerebral antifungal immunity. Previous work has shown that CARD9-positive microglia in the brain promote antifungal defence through interleukin-1β and CXCL1-mediated recruitment of neutrophils, and that microglial Toll-like receptor 4 and CD11b coordinate the eradication of cerebral C. albicans infection. Candidalysin, with its capacity to damage host cells and trigger pro-inflammatory signalling, appears to function as a double-edged sword: it injures tissue, but it also sounds the alarm that summons the immune cells needed to contain the fungus. Without both hyphae and toxin, the brain becomes permissive territory for uncontrolled fungal proliferation.

The twenty-one-day survival experiments complicated the picture further, and in doing so exposed the limits of using fungal burden as a proxy for disease severity. Wild-type infection yielded a survival rate of only twenty-five percent, confirming the lethality of the strain. Among single-deletion mutants, loss of HGC1 raised survival to sixty-seven percent and loss of SAP2 to seventy-five percent, while loss of ALS3 or ECE1 barely moved the needle at thirty-three and twenty-three percent respectively—indicating that hyphal growth and Sap2p, not candidalysin, are the strongest individual drivers of mortality in systemic disease. The multi-deletion data, however, introduced a fascinating nuance. The double mutant lacking ECE1 and HGC1 showed seventy-five percent survival, and the triple mutant lacking SAP2, ECE1 and HGC1 reached eighty-two percent, the highest of any strain tested. Yet the SAP2/ECE1 double mutant survived at only fifty percent—worse than the SAP2 single mutant at seventy-five percent—suggesting that the effect of losing candidalysin depends profoundly on the morphological and genetic context of the strain.

The authors propose a hypothesis to explain this context-dependence: candidalysin may play a dual role in systemic virulence. In strains that retain hyphal growth, such as the SAP2 mutant background, candidalysin may contribute to protective host responses including activation of the NLRP3 inflammasome and the induction of adaptive Th17 CD4 T-cell responses, which promote fungal clearance. Deleting ECE1 in such a background could reduce inflammation and thereby impair clearance, explaining the counterintuitively poor survival of the SAP2/ECE1 double mutant. Conversely, in a yeast-locked background such as the HGC1 mutant, where hyphal damage is already absent, candidalysin’s contribution tilts back toward pure virulence, and its deletion becomes protective. The authors are appropriately cautious, noting that group sizes limit statistical power and that dedicated studies interrogating host responses to this mutant panel will be required to confirm the hypothesis. Still, the idea that a fungal toxin could simultaneously be a virulence factor and an immune adjuvant whose net effect flips depending on fungal morphology is a provocative reframing of toxin biology.

Equally surprising was the behaviour of Als3p. Long regarded as a textbook virulence factor for its role in epithelial and endothelial adhesion and invasion, Als3p showed minimal influence on early brain fungal burden, consistent with prior reports that the adhesin is dispensable for virulence in disseminated candidiasis. But across all multi-deletion mutants, deletion of ALS3 consistently reduced survival, hinting at a previously underappreciated protective role. One possibility raised by the authors is that hyphal Als proteins act as ligands for complement receptor 3 on host immune cells, promoting receptor engagement and protective immune responses, or that Als3p contributes to NLRP3 inflammasome activation. If confirmed, this would add Als3p to the growing list of fungal virulence attributes that stimulate the very immune machinery they also subvert. Sap2p, meanwhile, showed only a modest reduction in brain burdens despite its known involvement in brain entry, a discrepancy the authors attribute to differences in experimental conditions and genetic backgrounds across studies—a caution about how strongly methodology shapes conclusions in this field.

The deeper lesson of the study is the uncoupling of fungal burden from disease outcome. High brain fungal loads correlated with deletion of HGC1 and ECE1, yet the same genes that failed to restrict brain growth also contributed, paradoxically, to long-term mortality: hyphal formation and Sap2p secretion were the key drivers of death in the survival experiments, while candidalysin played a lesser individual role. Fungal burden, the authors emphasise, does not necessarily reflect pathogenicity, because host-mediated tissue damage and organ dysfunction—rather than the sheer number of fungi—can determine disease severity. Virulence attributes simultaneously promote protective immune responses that restrict fungal growth and host damage that contributes to death, making any single snapshot of infection misleading. This framing challenges a widespread convention in preclinical infectious disease research, where organ colony counts are routinely treated as the definitive readout of virulence.

Taken together, the study identifies the critical combinatorial core of C. albicans systemic pathogenicity: hyphal growth accompanied by simultaneous candidalysin and Sap2p secretion. Deletion of all three factors produced the most attenuated strain, with survival climbing to eighty-two percent, while every partial combination left the fungus significantly dangerous. Beyond its mechanistic conclusions, the work demonstrates the value of building additive mutant panels in a single genetic background—a strategy that eliminates the confounding of strain background effects and permits genuinely systematic dissection of virulence networks. As fungal infections rise globally and antifungal drug development remains slow, understanding which virulence traits actually matter, and in what combinations, may guide the selection of drug targets and vaccine antigens that disarm the fungus without dismantling the immune signals that help clear it. The paradox that candidalysin can be both poison and alarm bell may prove central to that effort.